醫(yī)學(xué)全在線
醫(yī)學(xué)全在線首頁-醫(yī)師-藥師-護士-衛(wèi)生資格-高級職稱-考試題庫-網(wǎng)校-考研-圖譜-下載-招聘  
分類
國家級省級浙江省各省雜志
科技核心北大核心CSCDCSCD擴展
工具
期刊知識寫作指導(dǎo) 論文投稿推薦期刊
期刊驗證論文檢測 錄用通知往期目錄
SCI
SCI指導(dǎo)影響因子
期刊點評基金動態(tài)
其它
經(jīng)濟教育計算機
建筑體育農(nóng)業(yè)
北京|天津|河北|山西|湖北|江蘇|安徽|山東|上海|浙江|江西|福建|湖南|寧夏|內(nèi)蒙古|河南
四川|重慶|貴州|云南|遼寧|吉林|廣東|廣西|海南|陜西|甘肅|新疆|青海|衛(wèi)生部直屬|黑龍江|兵團
您現(xiàn)在的位置: 醫(yī)學(xué)全在線 > 醫(yī)學(xué)論文 > 論文投稿 > 正文:不同劑量阿托伐他汀對肺心病患者bigET及hsCRP及PAP水平的影響
    

醫(yī)學(xué)論文范文:不同劑量阿托伐他汀對肺心病患者bigET及hsCRP及PAP水平的影響

來源:本站原創(chuàng) 更新:2013-9-5 論文投稿平臺

醫(yī)學(xué)論文范文:不同劑量阿托伐他汀對肺心病患者bigET及hsCRP及PAP水平的影響

【摘要】 目的 對肺心病并高脂血癥患者應(yīng)用不同劑量阿托伐他汀治療,觀察其調(diào)脂的同時對大內(nèi)皮素(bigET)及超敏C反應(yīng)蛋白(hsCRP)的影響,及肺動脈壓力(PAP)改變情況。方法 將在我院就診的肺心病高脂血癥患者100例,隨機分為2組,即A組(阿托伐他汀10 mg,每晚1次)、B組(阿托伐他汀20 mg,每晚1次)。2組之間匹配非處理因素,比較2組治療24周后血脂水平,bigET及HsCRP、PAP變化情況。結(jié)果 2組在治療24周后血脂及內(nèi)皮功能、肺動脈壓力均有改善,血清hsCRP水平均有降低(P<0.05), B組24周后bigET水平及hsCRP水平明顯低于A組(P<0.05)。PAP改善B組較A組明顯(P<0.05)。2組之間不良反應(yīng)率間差異有統(tǒng)計學(xué)意義(P<0.01)。結(jié)論 他汀類藥物在調(diào)脂的同時具有非調(diào)脂依賴性心臟保護作用,可改善血管內(nèi)皮功能、抑制慢性炎癥反應(yīng),降低肺動脈壓力、改善心功能,并隨劑量的增加其作用增加。

【關(guān)鍵詞】 肺心病;高脂血癥;內(nèi)皮縮血管肽類;超敏C反應(yīng)蛋白;阿托伐他汀

Effects of different doses of atorvastatin on serum lipids, bigET, hsCRP and PAP in hyperlipidemia patients with chronic cor pulmonale ZHU Yanhui, WANG Xizhu, SONG Qiaofeng, et al.Department of Cardiology, People’s Hospital of Tangshan city,Hebei,Tangshan 063000,China

【Abstract】 Objective To investigate the safety and therapeutic effect of different doses of atorvastatin on lipidlowering,endothelial function,highsensitivity Creactive protein(hsCRP)and pulmonary artery pressure(PAP)in hyperlipidemia patients with chronic cor pulmonale.Methods 100 hyperlipidemia patients with chronic cor pulmonale were randomly divided into two groups.The patients in disorder lipidemia group were given atorvastatin 10mg qd or 20 mg qd for 24 weeks. The levels of TC, TG, LDLC, HDLC, bigET and hsCRP, PAP were determined in disorder lipidemia groups 24 hours after pretreatment or treatment.Results TC and LDLC were decreased significantly(P<0.05)in both groups after 24 weeks, but the decrease in atorvastatin 20mg qd group was more obvious. BigET in atorvastatin 20mg qd group was reduced from (0.69±0.26 )pmol/L before treatment to (0.43±0.07) pmol/L after 24week treatment,which also was significantly lower than that of atorvastatin 10mg qd group(0.51±0.08)pmol/L (P<0.05). hsCRP in atorvastatin 20mg qd group was decreased from(7.1±2.1)mg/L before treatment to(3.8±0.4)mg/L after 24week treatment, which was significantly lower than that of atorvastatin 10mg qd group(4.4±0.6) mg/L(P<0.05). PAP in atorvastatin 20mg qd group was reduced from(54±18)mmHg before treatment to(30±7)mmHg after 24week treatment, which was significantly lower than that of atorvastatin 10mg qd group(42±8)mmHg(P<0.05).Conclusion The atorvanstain can reduce obviously blood lipid,hsCRP and PAP,and can improve endothelial function. The administration of atorvanstain 20mg qd is safe, which is effective in controlling blood lipid,decreasing hsCRP,PAP and improving endothelial function醫(yī).學(xué)全.在.線網(wǎng)站jfsoft.net.cn.

【Key words】 pulmonary heart disease; hyperlipidemia; endothelins;highsensitivity Creactive protein;atorvastatin


[1] [2] [3] [4] [5] 下一頁

...
關(guān)于我們 - 聯(lián)系我們 -版權(quán)申明 -誠聘英才 - 網(wǎng)站地圖 - 網(wǎng)絡(luò)課程 - 幫助
醫(yī)學(xué)全在線 版權(quán)所有© CopyRight 2006-2046, MED126.COM, All Rights Reserved
浙ICP備12017320號
百度大聯(lián)盟認證綠色會員實名網(wǎng)站 360認證可信網(wǎng)站 中網(wǎng)驗證